Breaking News, Collaborations & Alliances

Endocyte & ITM Partner for Prostate Cancer

The supply agreement is for the phase 3 VISION trial

Endocyte and ITM have entered a supply agreement under which ITM will supply the medical radioisotope no-carrier-added lutetium, EndolucinBeta®, to support clinical supply of Lu-PSMA-617 for the phase 3 VISION trial expected to be initiated by Endocyte in the second quarter of 2018.   “ITM has been an innovator in the development of the highly purified form of lutetium-177, an integral component of the 177Lu-PSMA-617 therapy for the investigational treatment of prostate cancer,” said Mik...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters